Black Diamond Therapeutics, Inc. 09203E105 06/26/2026 Non-Binding Advisory Vote to Approve the Compensation of our Named Executive Officers SECTION 14A SAY-ON-PAY VOTES ISSUER 6206964 0 FOR 6206964 FOR Black Diamond Therapeutics, Inc. 09203E105 06/26/2026 Non-Binding Advisory Vote on the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of our Named Executive Officers SECTION 14A SAY-ON-PAY VOTES ISSUER 6206964 0 FOR 6206964 FOR CRISPR Therapeutics AG H17182108 06/04/2026 Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders SECTION 14A SAY-ON-PAY VOTES ISSUER 148831 0 FOR 148831 FOR CRISPR Therapeutics AG H17182108 06/04/2026 Binding vote on maximum equity for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders SECTION 14A SAY-ON-PAY VOTES ISSUER 148831 0 FOR 148831 FOR CRISPR Therapeutics AG H17182108 06/04/2026 Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027 SECTION 14A SAY-ON-PAY VOTES ISSUER 148831 0 FOR 148831 FOR CRISPR Therapeutics AG H17182108 06/04/2026 Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026 SECTION 14A SAY-ON-PAY VOTES ISSUER 148831 0 FOR 148831 FOR CRISPR Therapeutics AG H17182108 06/04/2026 Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders SECTION 14A SAY-ON-PAY VOTES ISSUER 148831 0 FOR 148831 FOR CRISPR Therapeutics AG H17182108 06/04/2026 Non-binding advisory vote on the 2025 Compensation Report SECTION 14A SAY-ON-PAY VOTES ISSUER 148831 0 FOR 148831 FOR CRISPR Therapeutics AG H17182108 06/04/2026 Non-Binding Advisory Vote on the Compensation Paid to the Company's Named Executive Officers Under U.S. Securities Law Requirements SECTION 14A SAY-ON-PAY VOTES ISSUER 148831 0 FOR 148831 FOR Skye Bioscience, Inc. 83086J200 05/26/2026 Approval of the Compensation of the Named Executive Officers SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Tempest Therapeutics, Inc. 87978U108 01/27/2026 Advisory Vote on Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 269772 0 FOR 269772 FOR